Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans

Systematic omics analysis identifies CCR6 as a therapeutic target to overcome cancer resistance to EGFR inhibitors

“… 25 , 26 , 27 These strategies are anticipated to overcome the limitations of current targeted therapeutics, including the low patient eligibility for drugs such as EGFRi, by identifying accompanying drugs with EGFRi based on molecular and phenotypic features observed in CCLs, thus effectively broadening the range of treatment options. 28 , 29 …”